WEST CHESTER, Ohio, June 5 /PRNewswire-FirstCall/ -- AtriCure, Inc. , a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to participate in the Leerink Swann & Company Rhythm Revival: Atrial Fibrillation Roundtable Conference at the Grand Hyatt New York on Wednesday, June 6th. At 2:15 p.m. ET, Mr. Drachman will participate in a panel discussion “Device-based Therapies for Atrial Fibrillation” and at 4:00 p.m. ET he will present the AtriCure investor presentation.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices designed to create precise lesions, or scars, in soft and cardiac tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatment alternative during open- heart surgical procedures to create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(R) clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system, including the new Isolator Synergy(TM) ablation clamps, for the ablation, or destruction, of soft tissues in general and non-cardiac related surgical procedures, but to date has not cleared or approved the system for cardiac use or for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Pen for the ablation of cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias, but the multifunctional bipolar Pen has not been approved for the treatment of AF.
Contacts: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 jpiton@atricure.com The Ruth Group Nick Laudico (investors) (646) 536-7030 nlaudico@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com
AtriCure, Inc.
CONTACT: media, Julie A. Piton, Vice President and Chief FinancialOfficer, AtriCure, Inc., +1-513-755-4561, or jpiton@atricure.com, or JasonRando of The Ruth Group, +1-646-536-7025, or jrando@theruthgroup.com, forAtriCure, Inc., or investors, Nick Laudico of The Ruth Group,+1-646-536-7030, or nlaudico@theruthgroup.com, for AtriCure, Inc.
